Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study

NCT04055909 is registered in ClinicalTrials.gov with Inotrem as lead sponsor.

NCT NCT04055909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
Lead sponsor
Inotrem
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2019
Completion date
May 9, 2023
Enrollment
355 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

shock, septic